Delving into the Latest Updates on Rotigotine with Synapse

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is caused by mutations in the PKD1 or PKD2 genes, which encode polycystins 1 and 2. Patients develop renal cysts associated with a progressive decline in kidney function, ultimately leading to end-stage renal disease in approximately one third of cases. ADPKD is also characterized by early-onset hypertension and cardiovascular complications, notably intracranial aneurysms.
This phenotype is related to abnormal polycystin function in the primary cilia of renal epithelial and vascular endothelial cells, resulting in impaired mechanotransduction of shear stress induced by urinary and blood flow and subsequent alterations in multiple cellular functions. Experimental studies have suggested that stimulation of dopamine receptor type 5 (DR5) may restore endothelial mechanosensitivity. This hypothesis is supported by our preliminary results showing that local administration of dopamine improves endothelial function in patients with ADPKD through restoration of nitric oxide (NO) release in response to increased blood flow.
Consistent with these findings, the IMPROVE-PKD study recently demonstrated similar beneficial effects on endothelial function and hemodynamics using rotigotine, a dopamine agonist administered via transdermal patches for two months at a low dose (4 mg/24 h). Dopaminergic stimulation may also prevent renal abnormalities related to polycystin deficiency. We therefore hypothesize that rotigotine could slow the progression of ADPKD at both the renal and cardiovascular levels.
This phase 2 study aims to evaluate the long-term tolerability of rotigotine in patients with ADPKD and to collect preliminary data on its effects on renal outcomes.

Start Date12 May 2026

Sponsor / Collaborator-

CTIS2025-521172-64-00

/ Not yet recruitingPhase 2

Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed Rotigotine 12 mg/24 h transdermal patch in patients with Parkinson’s disease

Start Date05 Jan 2026

Sponsor / Collaborator

Luye Pharma Switzerland AG

NCT07769359

/ CompletedPhase 1

Single Dose Bioequivalence and Adhesion Study of Rotigotina B7 TDS (2 mg/24h) (Rotigotine Transdermal Patch 2 mg/24 Hours) and 'NEUPRO®' (Rotigotine) 2 mg/24 Hours Transdermal Patch in Healthy Adult Human Participants.

This study was intended to demonstrate bioequivalence of the Amarin's Rotigotine patch respect to Neupro, (RLD), as well as non-inferiority in adhesion, when tested at a dose of 2 mg/24h in healthy subjects of both sexes. Local and systemic adverse events were also monitored and reported. Worn patches were recovered and analysed to compare residual drug.

Start Date04 Dec 2025

Sponsor / Collaborator

Cliantha Research Ltd.

100 Clinical Results associated with Rotigotine

Login to view more data

100 Translational Medicine associated with Rotigotine

Login to view more data

100 Patents (Medical) associated with Rotigotine

Login to view more data

743

Literatures (Medical) associated with Rotigotine

01 Nov 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Dual-acting molecular hybrid strategy: A dopamine D2 receptor agonist with synergistic anti-ferroptosis activity for the treatment of Parkinson's disease

Article

Author: Chen, En ; Inden, Masatoshi ; Funamoto, Kosei ; Ohuchi, Kazuki ; Kurita, Hisaka ; Zhu, Qi ; Murakami, Takanori ; Yu, Yongping ; Li, Haifeng ; Chen, Wenteng ; Yan, Zihan

Parkinson's disease (PD) is a progressive neurodegenerative disorder. Accumulating evidence suggests iron homeostasis in the substantia nigra pars compacta and the subsequent induction of ferroptosis play pivotal roles in PD pathogenesis. In this study, we proposed a dual-acting molecular hybrid strategy and identified a promising lead compound 27e. 27e exhibited potent agonistic activity on dopamine D2 receptor (EC₅₀ = 0.0325 nM), demonstrating 10-fold superior to clinical dopamine D2 agonist rotigotine (EC₅₀ = 0.301 nM). Moreover, 27e showed selective iron-chelating ability (K_b = 3.3 × 10²² M^-1), which enabled it to decrease intracellular ferrous iron levels and exert potent cytoprotective effects against iron-dependent ferroptosis in vitro. Additionally, 27e displayed weak cytotoxicity and acceptable blood-brain barrier permeability. In a mouse model of PD, treatment with 27e significantly ameliorated motor dysfunction compared to the vehicle group and showed better neuroprotective effects than rotigotine. Collectively, as a dual-acting molecule possessing dopamine D2 receptor agonism and ferroptosis inhibition, 27e offers a promising therapeutic strategy for PD that goes beyond symptomatic relief.

01 Oct 2026·AMERICAN JOURNAL OF OPHTHALMOLOGY

Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation

Article

Author: Chaaya, Celine ; Patel, Nimesh A ; Loya, Asad ; Weng, Christina Y ; Rahimy, Ehsan ; Muayad, Jawad ; Fazal, Owais ; Bordbar, Darius D ; Alsoudi, Amer F

PURPOSE:

Age-related macular degeneration (AMD) is a leading cause of central vision loss worldwide. Emerging evidence suggests that targeting dopaminergic pathways may influence AMD progression. This study evaluates whether levodopa ± carbidopa or dopamine receptor D2 (DRD2) agonists are associated with reduced risk of conversion to neovascular AMD (nAMD).

DESIGN:

Population-based clinical cohort study.

PARTICIPANTS:

Adults aged ≥18 years diagnosed with non-nAMD between May 2005 and May 2025, within the TriNetX US Collaborative Network, a federated electronic health record database spanning 69 healthcare organizations.

METHODS:

This retrospective cohort study emulated four distinct target trials comparing new users of (1) levodopa (± carbidopa) or (2) DRD2 agonists (pramipexole, ropinirole, bromocriptine, rotigotine, or cabergoline) to new users of two comparators (pantoprazole or gabapentin). Patients with prior nAMD or prescriptions of other dopamine-enhancing agents (eg, selegiline, rasagiline, tolcapone) were excluded. Each exposure group was independently matched to comparators using 1:1 propensity score matching for selected demographics, social factors, comorbidities, and AMD stage.

MAIN OUTCOME MEASURES:

The primary outcome was 3-year risk of conversion from non-nAMD to nAMD. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. An α level of 0.05 was used to determine statistical significance.

RESULTS:

Patients prescribed levodopa ± carbidopa had a reduced 3-year risk of conversion to nAMD relative to their matched counterparts prescribed pantoprazole (levodopa n = 1312, control n = 1312; HR 0.67; 95% CI, 0.45-0.98) and gabapentin (levodopa n = 1675, control n = 1675; HR 0.69; 95% CI, 0.50-0.95). No significant difference was observed in 3-year risk of conversion to nAMD between DRD2 agonists use relative to pantoprazole (DRD2 n = 1603, control n = 1603; HR 0.81; 95% CI, 0.58-1.13) or gabapentin (DRD2 n = 2779, control n = 2779; HR 0.92; 95% CI, 0.72-1.19).

CONCLUSIONS:

In this cohort study, levodopa ± carbidopa use was associated with lower 3-year risk of conversion to nAMD in two independent matched comparisons, whereas DRD2 agonists were not associated with significant differences in risk. These findings suggest dopaminergic signaling may influence AMD progression and warrant further prospective investigation.

01 Sep 2026·Kidney International Reports

Randomized Controlled Trial Evaluating Rotigotine Safety in PKD

Article

Author: Donnadieu, Nathalie ; Béchade, Clémence ; Ruault, Sophie ; Duhamel, Elise ; Puech, Philippe ; Choukroun, Gabriel ; Claudinot, Amandine ; Houivet, Estelle ; Dacher, Jean-Nicolas ; Bellien, Jérémy ; Dumont, Audrey ; Guerrot, Dominique ; Buchbach, Virginie ; Marty, Nell ; Prod'Homme, Sabrina ; Cour, Adrien ; Renard, Cédric ; Glowacki, François ; Van Wynsberghe, Margaux ; Quillard-Murraine, Muriel

23

News (Medical) associated with Rotigotine

15 Sep 2025

·www.fiercepharma.com

BMS sells controlling stake in historic US-China pharmaceutical joint venture

Bristol Myers Squibb originally linked up with China’s Sinopharm Foreign Trade to establish Sino-American Shanghai Squibb Pharmaceuticals as the first U.S.-China pharmaceutical joint venture back in 1982. More than 40 years after establishing the first U.S. pharmaceutical joint venture in China, Bristol Myers Squibb is handing over its controlling stake in the business.BMS has inked an agreement to sell a 60% ownership stake in its China-based joint venture Sino-American Shanghai Squibb Pharmaceuticals (SASS), a BMS spokesperson told Fierce Pharma in an emailed statement. The move is primarily related to manufacturing of older medicines and consumer products in China and doesn't affect Bristol's core business in the country.An internal email circulating online suggests Hillhouse Capital is on the other end of the transaction. Hillhouse is one of Asia’s biggest investment firms, having invested in such biopharma outfits as BeOne Medicines (formerly BeiGene) and Jiangsu Hengrui Pharmaceuticals. The BMS spokesperson didn’t address the buyer’s identity. “As part of our long-term strategy, we continue to align our resources to support evolving business needs across our global network,” the BMS spokesperson said. “The planned sale of our interest in the SASS joint venture reflects the continued implementation of our manufacturing strategy—one that balances internal capabilities with strong external partnerships to enhance regional focus and ensure long-term supply reliability for patients in China and around the world.”BMS will work to assist any employees impacted by the deal and is prioritizing a “smooth and respectful transition” during the ownership change, the spokesperson added. BMS did not elaborate on the financial terms of the agreement.Crucially, the news does not mean that BMS’ core innovative drugs business will cease operation in China. BMS originally linked up with China’s Sinopharm Foreign Trade to establish SASS as the first U.S.-China pharmaceutical joint venture back in 1982. When China opened its economy to foreign entities in the 1980s, multinational corporations were only allowed to enter the country through joint ventures with state-owned, local companies such as Sinopharm.BMS’ China joint venture operates a 58,000-square-meter (roughly 624,307-square-foot) manufacturing facility in Shanghai responsible for production of antibiotics, cardiovascular drugs, analgesics and metabolic medicines, according to the company’s website.BMS’ stake sale isn’t expected to disrupt facility operations or product supply in China. The transaction includes both the sale of the joint venture itself and products that SASS makes exclusively for the mainland China market, including the hepatitis antiviral Baraclude, the buffered aspirin product Bufferin, the vitamin deficiency supplement Theragran, Monopril for high blood pressure and heart failure, and Velosef, which is an antibiotic used to treat bacterial infections. Several other prescription or over-the-counter medicines are listed under the joint venture, according to a database managed by China’s National Medical Products Administration.These days, as China has become more amenable to foreign entities’ participation in the domestic market, legacy joint ventures established by Western drugmakers often maintain a mix of older drug brands, off-patent medicines and consumer products separate from the companies’ innovative therapeutics businesses.Meanwhile, BMS isn’t the only ex-China drugmaker to dispense with certain legacy brands in the country. Last August, Belgium’s UCB said it was selling its mature neurology and allergy business in mainland China to local healthcare asset manager CBC Group and the Abu Dhabi-based investment organization Mubadala in a deal worth $680 million.The deal covered the divestment of seizure drugs Keppra and Vimpat, Neupro for Parkinson’s disease and restless leg syndrome, and the allergy meds Zyrtec and Xyzal, as well as a manufacturing facility in the city of Zhuhai, located in China’s Guangdong Province.The deal was designed, in part, to free up UCB’s focus on potential innovative medicine launches across immunology, neurology and rare diseases in China, the company’s CEO, Jean-Christophe Tellier, said at the time.

AcquisitionLicense out/in

02 Dec 2024

·www.pharmaindustrial-india.com

CBC Group Acquires UCB's Mature Product Portfolio in China

CBC Group has completed the acquisition of global biopharmaceutical company UCB's mature neurology and allergy business in China, in partnership with Mubadala Investment Company, the Abu Dhabi based global investment company. The acquisition marks another successful transaction under CBC's buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in China while expanding CBC's portfolio within the region's dynamic pharmaceutical market. The transaction, valued at USD 680 million, includes UCB's well-known brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and the Zhuhai manufacturing site. The well-established and trusted medicine portfolio will serve as an anchor asset as CBC builds out a leading integrated central nervous system (CNS) biopharma platform in China, where the market size has reached USD 33 billion. Beyond strengthening CBC's presence in the rapidly growing Chinese healthcare market, the acquisition also enhances the firm's capabilities in meeting the rising demand for neurology and allergy treatments in the wider region. In collaboration with Mubadala, CBC will tap on its proprietary investor-operator approach, deep healthcare expertise and platform synergies to drive operational efficiencies, innovation and scale to benefit more patients across the region. Fu Wei, Chief Executive Officer of CBC Group, said, "There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today's healthcare investing market. Together, we are making a profound impact on the industry by harnessing our combined expertise and capital to not only enhance patient outcomes but also build value for our stakeholders. Leveraging our joint strengths, we are poised to capitalize on synergies and deploy hands-on strategic guidance to make significant strides in CNS market access and innovation." Named 'NeuroGen Pharma', the new company embodies what CBC and Mubadala envision for neuro healthcare innovation. The company will be led by a deep and experienced management team with an extensive track record in the biopharma industry, ensuring a smooth transition to propel it into the next phase of growth. NeuroGen Pharma is expected to deliver quality treatments to a wider reach of patients and play an important role in addressing the evolving neurology treatment needs in China. The company aims to leverage innovative therapies and cutting-edge research to enhance patient outcomes and shape the future of neurology care in the region. Combined net sales for the acquired portfolio in this transaction were Euro131 million in 2023. The strategic acquisition builds on CBC's collaboration with Mubadala, which includes their investment in CBC Healthcare Infrastructure Platform's (HIP) first life science real assets venture and the joint investment in the USD 315 million fundraising round for CBC-backed Hasten, a leading pharmaceutical company. Mohamed Albadr, Head of Asia at Mubadala, said, "We are thrilled to partner with CBC Group to support the growth and development of NeuroGen Pharma as it scales to a leading entity in China and delivers transformative medicines to patients. Built on a strong foundation of proven therapies and driven by innovation and cutting-edge research, the company is uniquely positioned to address the growing need for advanced neurology and allergy treatments while aligning with our commitment to enhancing access to care and growth in the healthcare system." Jean-Christophe Tellier, CEO at UCB, said, "In the short term, UCB is exploring the launch of novel medicines in immunology, neurology, and rare diseases in China. Our dedication to serving patients with unmet needs in China remains steadfast. Building on our 28-year presence in the country, we are committed to driving patient outcomes through continued collaboration with local partners and fostering innovation. We are convinced that the CBC Group and Mubadala are the ideal partners to advance the medicine portfolio and continue to improve the lives of people living with neurology and allergy diseases in mainland China."

Acquisition

02 Dec 2024

·www.pharmaceutical-technology.com

CBC acquires UCB’s neurology and allergy business in China

The new company aims to deliver quality treatments and address evolving neurology treatment needs in the country. Credit: Volha_R/Shutterstock. CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge’s ( UCB ) mature neurology and allergy business in China for $680m. The move comes after UCB agreed to sell and license its business in August 2024. The deal encompasses UCB’s Zhuhai manufacturing site and its brands Xyzal, Keppra, Zyrtec, Vimpat and Neupro. They are set to be the cornerstone assets for CBC as it develops an integrated central nervous system (CNS) biopharma platform in China. Working alongside Mubadala, CBC plans to leverage its platform synergies, investor-operator approach and healthcare expertise, to optimise operations, foster innovation and expand its reach to benefit more patients in the region. The new entity formed from this acquisition called NeuroGen Pharma is set to offer neuro healthcare innovation services. It will be spearheaded by a management team with a solid background in the biopharma industry, which is expected to ensure a seamless transition and drive future growth. The company aims to deliver quality treatments and address the evolving neurology treatment needs in the country. The acquired portfolio reported combined net sales of €131m ($138m) in 2023. The strategic acquisition is part of a broader partnership between CBC and Mubadala, which also includes their joint investment in the $315m fundraising round for Hasten and an investment in CBC Healthcare Infrastructure Platform’s first life science real assets venture. CBC Group CEO Fu Wei stated: “There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. “This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today’s healthcare investing market.”

Acquisition

100 Deals associated with Rotigotine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05768	Rotigotine	N04BC09	DB05271

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Parkinson Disease	European Union	UCB Pharma SA	15 Feb 2006
Parkinson Disease	Iceland	UCB Pharma SA	15 Feb 2006
Parkinson Disease	Liechtenstein	UCB Pharma SA	15 Feb 2006
Parkinson Disease	Norway	UCB Pharma SA	15 Feb 2006
Parkinson Disease	United Kingdom	UCB PHARMA LIMITED	15 Feb 2006
Restless Legs Syndrome	European Union	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	Iceland	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	Liechtenstein	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	Norway	UCB Pharma SA	15 Feb 2006
Restless Legs Syndrome	United Kingdom	UCB PHARMA LIMITED	15 Feb 2006

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Parkinson's disease	Phase 3	China	Shandong Luye Pharmaceutical Co., Ltd.	03 Feb 2020
Kidney Failure, Chronic	Phase 3	United States	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Austria	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Finland	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	France	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Germany	UCB BioSciences GmbH	01 Apr 2012
Kidney Failure, Chronic	Phase 3	Italy	UCB BioSciences GmbH	01 Apr 2012
Gastrointestinal dysfunction	Phase 3	United States	UCB Pharma GmbH	01 Jan 2012
Dyssomnias	Phase 3	Germany	UCB Pharma GmbH	01 Nov 2004
Young onset Parkinson disease	Phase 3	Australia	UCB Pharma GmbH	01 Aug 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MDS2025	Phase 3	Parkinson Disease	294	LY03003	kiirzbqyzz(ywvkxgekzt) = ajvmdllddl jzrnazbyvt (ntvexumcoe ) View more	Positive	05 Oct 2025
				Placebo	kiirzbqyzz(ywvkxgekzt) = iejwenhxdc jzrnazbyvt (ntvexumcoe ) View more
NCT03992196 (CTgov)	Phase 3	Restless Legs Syndrome	10	Rotigotine (Rotigotine Final Dose 2 mg/24 h)	ccngdsagla = ecfjegywpp rlrmmequpn (bgypybfysq, qyaufhdudt - ejlqoknkgz) View more	-	30 Oct 2023
				Rotigotine (Rotigotine Final Dose 3 mg/24 h)	ccngdsagla = qubrngptfr rlrmmequpn (bgypybfysq, vrfpksuodk - tnkgieehio) View more
NCT03728933 (CTgov)	Phase 3	Restless Legs Syndrome	23	Placebo	vaicatzcqc(kiddcwlxwt) = jiwginidya njnwxxrwtp (hscqjhbsrt, 6.8) View more	-	26 Oct 2023
NCT04937452 (CTAD2023)	Phase 2	Frontotemporal Dementia	75	Rotigotine 4 mg/day	cmrjmtaopm(cowxdydmze) = gzlmdznqht ztnntofmnu (lpjvipnuxt, −0.669 - 1.037)	Negative	24 Oct 2023
				Rotigotine 6 mg/day	cmrjmtaopm(cowxdydmze) = lwfyfwdwnl ztnntofmnu (lpjvipnuxt, − 0.225 - 1.037)
NCT04571164 (NEWS) Manual	Phase 3	Parkinson Disease	294	LY03003	glyszwqswa(wpkbpcmiys) = ，與安慰劑組相比，LY 03003組統一帕金森病評分量表(UPDRS)Ⅱ+Ⅲ評分較基綫顯著改善，兩組差異具有統計學意義（ P＜0.001 ）。 tjmaliabqq (vparqnzowl ) View more	Positive	19 Jul 2022
				Placebo
NCT02365870 (ANXPD, CTgov)	Phase 4	Anxiety Disorders \| Parkinson Disease	4	rotigotine transdermal patch (Rotigotine)	vdudjhlfsn(dybprngoyc) = doagegslmj ttjxdipeqc (qfqgopomwo, 0) View more	-	19 Mar 2020
				placebo (Placebo)	vdudjhlfsn(dybprngoyc) = wlqnpvbuwv ttjxdipeqc (qfqgopomwo, 5.1) View more
NCT03103919 (CTgov)	Phase 4	Parkinson Disease, Secondary \| Parkinson Disease	40	Kinesia-ONE™+Rotigotine (Rotigotine + Standard Care)	cdnwopywse(dakwclxltw) = oduktjzfvp bcwgoikqcv (twcclnuurv, sgsacdvqzk - tubhzsdrcy) View more	-	19 Feb 2019
				Kinesia-360™+Rotigotine (Rotigotine + Standard Care + Kinesia-360™ Wearable Device)	cdnwopywse(dakwclxltw) = ngkhbhovan bcwgoikqcv (twcclnuurv, qtscrwazmy - cljzzchgio) View more
NCT02230904 (PD0018, Pubmed \| Curr Med Res Opin) Manual	Phase 1	Parkinson Disease	57	rotigotine (Treatments A)	ijyyomqxzf(nuvasrzjfd) = irctgvrcdd sebhlxtzly (ybxxjrblxl, 1.635) View more	Positive	01 Jul 2018
				rotigotine (Treatments B)	kyajxxkjbd(pllbfdbzuw) = yazwbddojz uaybbznsvu (fgmqlnvtvj )
NCT01646255 (SP1037, Pubmed \| Parkinsonism Relat Disord 1 \| Parkinsonism Relat Disord 2) Manual	Phase 3	Parkinson Disease	346	Rotigotine	nqpshvsysw(fkqereamsb): difference = -1.20 (95% CI, -1.83 to -0.57), P-Value = 0.0002 View more	Positive	01 Nov 2017
				Placebo
NCT01495793 (Pubmed \| Sleep Med)	Phase 2	Restless Legs Syndrome	24	Rotigotine transdermal system 0.5 mg/24 h	ppkqnzblay(xgcuzbffnl) = yossicphba cuwkeexrzc (xhqzpblomc ) View more	-	01 Apr 2017
				Rotigotine transdermal system 1 mg/24 h	ppkqnzblay(xgcuzbffnl) = baurvxsljc cuwkeexrzc (xhqzpblomc ) View more